Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06682299 · ClinicalTrials.gov registry record · NA
Maintenance TMS in Treatment Resistant Depression
A NA study of Treatment Resistant Depression (TRD), sponsored by Austin Messner.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06682299: Recruiting NA study of Treatment Resistant Depression (TRD), sponsored by Austin Messner.
NCT06682299 is a NA study of Treatment Resistant Depression (TRD) that is actively recruiting participants, run by Austin Messner. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06682299, a NA study of Treatment Resistant Depression (TRD), is actively recruiting participants, sponsored by Austin Messner.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use. These barriers include procedure tolerability, cognitive side effects, financial burden, and unreliable social support to accompany patients for these treatments. On the other hand, a different modality of noninvasive neuromodulation called transcranial magnetic stimulation (TMS) can be performed in the outpatient setting and does not need anesthesia. The likelihood of cognitive adverse effects with TMS is much lower than with ECT. Our clinical question encompasses piloting a maintenance TMS regimen to maintain remission in treatment-resistant major depressive disorder. This will be a patient-preference clinical trial, with patients offered the choice to initiate maintenance TMS versus maintenance ECT after their index ECT sessions for treatment-resistant depression. There will be no randomization or placebo involved in this study.
Primary Outcome
One of the most widely used clinician administered depression scales containing 17 items. Scores range from 0 to 54 with 0-7 being normal, 8-16 being mild depression, 17-23 moderate depression and 24 or greater being severe depression. Higher scores equate to more severe depressive symptoms.
Conditions Studied
Interventions
- DEVICE Transmagnetic Stimulation
- DEVICE Electroconvulsive Therapy
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2026-04-01 |
| Phase | NA |
What NCT06682299 shows while recruiting
NCT06682299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Treatment Resistant Depression (TRD) appearing as the primary indexed condition, and to 2 interventions - of which Transmagnetic Stimulation is the first listed.
NCT06682299 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06682299 about?
NCT06682299 is a clinical study titled "Maintenance TMS in Treatment Resistant Depression". Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use. These barriers include procedure tolerability, cognitive side effects, financia...
What is the current status of trial NCT06682299?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-04-17. Estimated completion is 2026-04-01.
What conditions does trial NCT06682299 study?
This clinical trial studies the following conditions: Treatment Resistant Depression (TRD).
What interventions are being tested in trial NCT06682299?
The interventions under investigation include: Transmagnetic Stimulation (DEVICE), Electroconvulsive Therapy (DEVICE).
Who is sponsoring clinical trial NCT06682299?
This trial is sponsored by Austin Messner, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06682299 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment Resistant Depression (TRD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06682299's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI